Literature DB >> 30229546

Brief Overview of Prostate Cancer Statistics, Grading, Diagnosis and Treatment Strategies.

Heide Schatten1.   

Abstract

This chapter provides a brief overview of prostate cancer statistics, grading, diagnosis and treatment strategies that are discussed in more detail in the subsequent chapters of this book and the companion book titled "Clinical Molecular and Diagnostic Imaging of Prostate Cancer and Treatment Strategies". It also points to websites that provide additional useful information for patients affected by prostate cancer and for students and teachers to obtain practical and updated information on research, new diagnostic modalities and new therapies including new updated clinical trials. Three sections are focused on overview of prostate cancer statistics; overview of detection, diagnosis, stages and grading of prostate cancer; and treatment possibilities and options.

Entities:  

Keywords:  Chemotherapy; Cytoskeleton; Diagnosis; Grading; Metastasis; Microfilaments; Microtubules; Prostate cancer; Treatment

Mesh:

Year:  2018        PMID: 30229546     DOI: 10.1007/978-3-319-95693-0_1

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  33 in total

1.  MiR-1273 g-3p Promotes Malignant Progression and has Prognostic Implications in Prostate Cancer.

Authors:  Yaxue Chang; Qian Deng; Zhenfeng Guan; Yongyi Cheng; Yi Sun
Journal:  Mol Biotechnol       Date:  2021-08-24       Impact factor: 2.695

Review 2.  ATP-gated P2X7 receptor as a potential target for prostate cancer.

Authors:  Cuicui Qiao; Yiqing Tang; Qianqian Li; Xiaodi Zhu; Xiaoxiang Peng; Ronglan Zhao
Journal:  Hum Cell       Date:  2022-06-03       Impact factor: 4.374

Review 3.  The role of ferroptosis in prostate cancer: a novel therapeutic strategy.

Authors:  Yue Wang; Yifan Ma; Kui Jiang
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-09-02       Impact factor: 5.455

Review 4.  The regulatory function of piRNA/PIWI complex in cancer and other human diseases: The role of DNA methylation.

Authors:  Dong-Dong Jia; Hui Jiang; Yi-Fei Zhang; Yu Zhang; Li-Li Qian; Yin-Feng Zhang
Journal:  Int J Biol Sci       Date:  2022-05-09       Impact factor: 10.750

5.  Clinical Efficacy and Psychological Impact of Omaha-Based Continuing Care for Prostate Cancer Patients.

Authors:  Lanfang Luo; Fangfang Wang; Ling Wang; Jing Zhang; Xiaoyu Liu; Weifen Wang
Journal:  Comput Math Methods Med       Date:  2022-07-05       Impact factor: 2.809

6.  LINC00893 inhibits the progression of prostate cancer through miR-3173-5p/SOCS3/JAK2/STAT3 pathway.

Authors:  Chuigong Yu; Yu Fan; Yu Zhang; Lupeng Liu; Gang Guo
Journal:  Cancer Cell Int       Date:  2022-07-10       Impact factor: 6.429

7.  STK10 knockout inhibits cell migration and promotes cell proliferation via modulating the activity of ERM and p38 MAPK in prostate cancer cells.

Authors:  Lu Zhang; Shun-Yuan Lu; Rui Guo; Jin-Xia Ma; Ling-Yun Tang; Jin-Jin Wang; Chun-Ling Shen; Li-Ming Lu; Jie Liu; Zhu-Gang Wang; Hong-Xin Zhang
Journal:  Exp Ther Med       Date:  2021-06-08       Impact factor: 2.447

8.  Exosomal Circ-XIAP Promotes Docetaxel Resistance in Prostate Cancer by Regulating miR-1182/TPD52 Axis.

Authors:  Hui Zhang; Minghui Li; Jing Zhang; Yanbing Shen; Qi Gui
Journal:  Drug Des Devel Ther       Date:  2021-05-03       Impact factor: 4.162

9.  Analysis of Clinical Trials on Therapies for Prostate Cancer in Mainland China and Globally from 2010 to 2020.

Authors:  Kun Chen; Kehua Jiang; Lannan Tang; Xiaolong Chen; Jianxin Hu; Fa Sun
Journal:  Front Oncol       Date:  2021-05-12       Impact factor: 6.244

10.  Androgen-targeting therapeutics mitigate the adverse effect of GnRH agonist on the risk of neurodegenerative disease in men treated for prostate cancer.

Authors:  Gregory L Branigan; Georgina Torrandell-Haro; Maira Soto; Edward P Gelmann; Francesca Vitali; Kathleen E Rodgers; Roberta Diaz Brinton
Journal:  Cancer Med       Date:  2022-03-16       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.